University of Texas at Dallas

Dr. Ted Price is an Associate Professor in the School of Behavioral and Brain Sciences at the University of Texas at Dallas. He is one of the foremost researchers in understanding how neuronal plasticity alters the way the brain receives nociceptive information from the sensory system and how this relates to chronic pain in human patients. Dr. Price has discovered several novel targets that regulate the excitability of sensory neurons after injury and that mediate plasticity in the central nervous system that cause pain to become chronic. His work has been published in numerous scientific journals and his research program has been supported by the National Institutes of Health and the Migraine Research Foundation. He serves as an editor for several leading industry journals and received the Patrick D. Wall Young Investigator Award from the International Association for the Study of Pain.


University of California, Los Angeles

Kalyanam Shivkumar, MD, Ph.D., is Professor of Medicine (Cardiology), Radiology & Bioengineering at the University of California-Los Angeles, as well as Director of the UCLA Cardiac Arrhythmia Center & EP Programs. He leads a large group at UCLA–comprising a diverse group of 15 faculty members, several trainees and 60 staff professionals–involved in clinical care, teaching, research and biomedical innovation. The team provides state of the art clinical care and has developed several innovative therapies (e.g., epicardial ablation, neuromodulation) for the non-pharmacological management of cardiac arrhythmias and other cardiac structural problems. 


Bayer AG

Carla Klattenhoff, Ph.D., is a senior director of preclinical research in the cardiovascular department at Bayer AG and heads the Precision Cardiology Laboratory jointly with Patrick Ellinor. Her work focuses on discovery and validation of novel therapeutic targets for the treatment of cardiovascular and metabolic diseases by integrating data from snRNA sequencing, human genetics, and cell-based functional assays.


New York University

Rajesh Khanna, Ph.D., an internationally known expert in pain research, is the Director of the New York University Pain Research Center. His scientific investigations have generated new insight into the biologic mechanisms of pain, accelerated the pace of discovery in pain research, and laid the ground work for the development of a new category of non-opioid pain reliever. In addition to his scientific contributions, he has been awarded five patents for the treatment of pain. He also cofounded the company, Regulonix, LLC, and is the chief scientific officer of this early-stage biotechnology company.


University of Louisville

Dr. Tamer Mohamed is Associate Professor of Medicine at the University of Louisville School of Medicine. He completed his Ph.D. at the University of Manchester in the United Kingdom. He then completed his post-doctoral training at the J. David Gladstone Research Institute to identify novel therapies for heart failure. He’s published more than 25 papers in reputed international journals and has been awarded several prestigious awards, including the Young Investigator Award and the Arnold Katz Award. Dr. Mohamed’s main research interest is to identify novel therapies for heart failure focusing on endogenous heart repair and regeneration mechanisms, as well as focus on translational research that directly benefits heart failure patients.


Carleton University

Dr. Mike Hildebrand completed his Ph.D. in cellular neuroscience in Terry Snutch’s lab at UBC. Using patch-clamp electrophysiological techniques, he characterized how the regulation of voltage-gated calcium channels impacts neuronal excitability. Dr. Hildebrand later pursued an industrial R&D fellowship at Zalicus Pharmaceuticals in Vancouver, where he developed an ex vivo rodent spinal cord recording assay for Zalicus’ preclinical pain research program. Dr. Hildebrand is now leading his own pain research program as an Associate Professor at Carleton University and Affiliate Investigator at The Ottawa Hospital, where his team is studying both acute and chronic pain processing using animal and human tissue models.


Lassen Therapeutics

Jamie Swaney, Ph.D., is Vice President of Fibrosis and Translational Biology at Lassen Therapeutics and has more than 17 years of drug development experience in tissue fibrosis/remodeling and inflammation. Prior to joining Lassen, Jamie was Executive Director and head of fibrosis at Metacrine, leading small molecule programs for NASH liver fibrosis. He has contributed to several patents and authored multiple peer-reviewed publications. Jamie received a Ph.D. in Molecular Pathology from the University of California at San Diego and holds an M.S. from the University of San Diego and a B.S. from the University of California at Santa Barbara.


Stanford University

Dr. David C. Yeomans, Ph.D., is a Professor in the Department of Anesthesia at Stanford Medical School. He is also Director of Pain Research and of the Medical Neuroscientist Program at Stanford. His current academic interests focus primarily on gene therapy for chronic pain and biomarkers for different pain types. In addition to his academic work, Dr. Yeomans has also been instrumental in the development of several novel therapeutic approaches to pain, working with biotech, pharma, and intellectual property companies.


Harvard University

Dr. Krishnan is the Associate Professor of Emergency Medicine at the Beth Israel Deaconess Medical Center at Harvard University. He is broadly interested in lung (patho)physiology, cell mechanics and the relationships between the two. His current focus is asthma exacerbation. His laboratory has elucidated key roles in airway smooth muscle contraction, extracellular matrix stiffening and a failure of a deep breath to stretch the airway wall.


Cornell University

Dr. Schwartz is an Associate Professor of Medicine at Weill Cornell Medicine and an Attending Physician at the New York-Presbyterian Hospital Cornell campus. In his patient practice, Dr. Schwartz focuses on the care of patients with liver disease. His interests include viral hepatitis, autoimmune causes of liver disease and Non-Alcoholic Fatty Liver Disease, as well as metabolic causes of liver disease. He uses stem cell biology, hepatocyte biology and incorporates engineering techniques to better understand human liver disease with the goal to improve clinical therapy.


Aslan Pharmaceuticals

Ferda Cevikbas, Ph.D., is Head of Translational Sciences at Aslan Pharmaceuticals, a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments based in Palo Alto, California. Prior to that, she was a Senior Clinical Research Advisor for Eli Lilly, and the Director of Translational Neuroscience and Dermatology at Dermira.



Najah Abi-Gerges, Ph.D., is Vice President of Research & Development at AnaBios. With over 17 years in the pharmaceutical industry, he is an innovative leader, having made substantial contributions to drug approvals, research across several areas of cardiac physiology and pharmacology resulting in over 40 published peer-reviewed articles and novel paradigms to advance cardiovascular translational science. Dr. Abi-Gerges is editor for the Journal of Pharmacological and Toxicological Methods, and is also a reviewer for more than 20 peer-reviewed scientific journals and review judge panel for various science institutes and foundations. Dr. Abi-Gerges is co-chair of the ion channel group in the CiPA initiative.


Grünenthal Group

Eric Nisenbaum, Ph.D., is the Sr. Vice President, Head Boston Innovation Hub at Grünenthal Group. During the course of his career in pharmaceutical science, his research has focused on the identification and delivery of novel therapeutic approaches to address the significant unmet needs of patients suffering from neurological and psychiatric disorders.


National Institutes of Health

Michael Iadarola, Ph.D., is currently a Senior Research Scientist in the Department of Perioperative Medicine, Clinical Center of the National Institutes of Health. He received his doctoral training in pharmacology at Georgetown University Medical School. At the Clinical Center, he is currently involved in a clinical-translational research program exploring treatment of patients with resiniferatoxin (RTX) to modify TRPV1 neurons and produce analgesia. In 2014, he received the Frederick W. L. Kerr Basic Science Research Award from the American Pain Society.


Aligos Therapeutics

Dinah Misner, Ph.D., is the Vice President of Aligos Therapeutics, located in San Francisco, California. Prior to her time at Aligos, she was Scientific Director of Toxicology at Alios BioPharma. She has also worked for Genentech, Celgene and Roche.


Icahn School of Medicine at Mount Sinai

Hina Chaudhry, MD is Professor of Medicine and Cardiology and Director of Cardiovascular Regenerative Medicine at Icahn School of Medicine at Mount Sinai. Dr. Chaudhry was previously Florence Irving Assistant Professor of Medicine at Columbia University College of Physicians and Surgeons. She holds multiple patents in the areas of cell cycle manipulation for heart repair and the use of placental stem cells for heart repair. She has been honored by many organizations for her work in cardiac regeneration, including TEDMED Innovation Scholar, Clinician Scientist Award and Best Manuscript Award of the American Heart Association, and has served as Principal Scientist for the New York State Stem Cell Board. She has been funded by the NIH, AHA, New York Stem Cell Board, and Broadview Ventures. In fact, she has held continuous, competitive funding for her research since Year 2 of her cardiology fellowship, now a span of over 20 years. She is also a staunch supporter of women in STEM, having spoken on this topic at both the White House, under the Obama administration,  and twice at the United Nations International Day of Women and Girls in Science. She lectures worldwide in her research field and has been an expert commentator for CNN.


Gilead Sciences

Dr. Yurong Lai, Ph.D., MD, FAAPS, has than 20 years in pharmacology research and 18+ years of drug development experience. He is currently the Director of Drug Metabolism at Gilead Sciences, where he manages DM-drug disposition labs to implement in vitro/in vivo preclinical/clinical strategies for compound advancement to regulatory filing. Dr. Lai also holds an adjunct faculty position in the Department of Pharmacy of the University of Rhode Island. He received his M.D from Fujian Medical University in China and his Ph.D. (Toxicology) from Sapporo Medical University in Japan in 1998. From 1998 to 2001, he was a research fellow of Japanese Society for Promotion in Department of Physiopathology, Graduate School of Medicine of Hokkaido University, followed by a position as Research Associate in Department of Pharmaceutics at the University of Washington.